Fuse Medical entered into a distribution partnership with BRM Extremities for the exclusive U.S. national distribution of the Silktoe® metatarsophalangeal joint arthroplasty implant. This is the latest addition to Fuse’s portfolio of lower extremity products.
Silktoe offers an alternative to fusion for patients with severe arthritis in the metatarsophalangeal joint. The design is derived from historical silastic toe arthroplasty devices and evolved to offer a more anatomical fit and replication of natural anatomical motion.
The system comprises an elastomeric silicone spacer placed within each of the two bones comprising the metatarsophalangeal joint during toe arthroplasty and secured in place by titanium grommets. Available in five different sizes specific to the left or right foot, Silktoe is sterile packaged and ready for implantation.
Silktoe is intended for arthroplasty of the first metatarsophalangeal joint (MTP1) of the foot. It represents a permanent implant, used in all severe forms of arthritis, such as: hallux rigidus or hallux limitus, painful rheumatoid arthritis, hallux abducto valgus associated with arthritis, or unstable or painful joint from previous surgery.
“Adding Silktoe to our lower extremity portfolio aligns with Fuse’s focus on delivering products based on replication of anatomical motion,” commented Christopher C. Reeg, Chief Executive Officer of Fuse. “Historical designs that led to the evolution of Silktoe have a significant history in the lower extremity market. While there are other options available, we believe the versatility of the device is superior to other toe arthroplasty products. We are excited to partner with BRM and look forward to expanding our distribution footprint with them in the U.S. market.”
Source: Fuse Medical, Inc.